{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:50:10Z","timestamp":1788511810663,"version":"build-2803163510"},"reference-count":30,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>\n                    The MWRI-01 study characterized the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of rilpivirine (RPV) long acting (LA) in a model of preexposure prophylaxis (PrEP). Prospective, open-label Phase 1 study. The safety and acceptability of three repeated doses of RPV LA were monitored. Blood, tissue (rectal, cervical, and vaginal), and biological fluids (vaginal and endocervical) were collected at baseline and at 1- to 2-month intervals throughout the study for PK and PD assessment. Eight women and four men received three intramuscular doses of 1,200\u2009mg of RPV LA given 8 weeks apart. There were a total of 195 adverse events (AEs) reported, of which 138 (70.8%) were Grade 1 and 55 (28.2%) were Grade 2. The most common AE was injection site pain. Geometric mean (90% confidence interval) plasma RPV concentrations at 56 days after the first and third doses were 39 (33\u201345) ng\/mL (female)\/29 (17\u201340) ng\/mL (male) and 59 (45\u201362) ng\/mL (female)\/40 (30\u201351) ng\/mL (male), respectively. Exposure to RPV LA was associated with significant inhibition of HIV-1\n                    <jats:sub>BaL<\/jats:sub>\n                    viral replication in the\n                    <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                    rectal explant model (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u2009.0001) that persisted for up to 4 months after the third dose of RPV LA. In contrast, no viral suppression was seen in cervicovaginal tissue. Multiple dose administration of RPV LA was safe and well tolerated, and was associated with prolonged suppression of viral replication in rectal explant tissue.\n                  <\/jats:p>","DOI":"10.1089\/aid.2018.0265","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T05:00:51Z","timestamp":1559278851000},"page":"794-804","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV"],"prefix":"10.1177","volume":"35","author":[{"given":"Ross D.","family":"Cranston","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene S.","family":"Dezzutti","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."},{"name":"Magee Women Research Institute, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Siegel","sequence":"additional","affiliation":[{"name":"Magee Women Research Institute, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarret","family":"Engstrom","sequence":"additional","affiliation":[{"name":"Magee Women Research Institute, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Shetler","sequence":"additional","affiliation":[{"name":"Magee Women Research Institute, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Richardson-Harman","sequence":"additional","affiliation":[{"name":"Alpha StatConsult, LLC, Damascus, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Egan","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Egan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Stall","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Williams","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda M.","family":"Brand","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi M.","family":"Parikh","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McGowan","sequence":"additional","affiliation":[{"name":"Orion Biotechnology, Ottawa, Canada."},{"name":"University of Miami, Miller School of Medicine, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-017-0391-6"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000160"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.118"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30113-8"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2013.809535"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159517"},{"key":"e_1_3_5_13_2","unstructured":"Friedman ESD Rudd DJ Fox-Bosetti S et al.: A single monotherapy dose of MK-8591 a Novel NRTI suppresses HIV for 10 days. In: Conference on Retroviruses and Opportunistic Infections Boston 2016 437LB."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.863708"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","unstructured":"Snyder O Vincent H Lachau-Durant S Kraus G Williams P Garcia JV. Preclinical evaluation of TMC-278 LA a long-acting formulation of rilpivirine demonstrates significant protection from vaginal HIV infection. In: HIV R4P Meeting Cape Town Abstract OA03 01 2014.","DOI":"10.1089\/aid.2014.5010.abstract"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00011"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(01)00295-6"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00255-2"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.59"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0262"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111507"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023243"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318291f331"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01805-16"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-123"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00986-09"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00224-8"},{"key":"e_1_3_5_29_2","unstructured":"Bekker LG Li SS Tolley B et al.: HPTN 076: TMC278 LA safe tolerable and acceptable for HIV preexposure prophylaxis. In: Conference on Retroviruses and Opportunistic Infections Seattle WA 2017 421LB."},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00167-16"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv528"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2018.0265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:14:44Z","timestamp":1777367684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2018.0265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1089\/aid.2018.0265"],"URL":"https:\/\/doi.org\/10.1089\/aid.2018.0265","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}